Replies to post #141332 on Avid Bioservices Inc (CDMO)

[ku]

Eyebuystox, thanks I respect your post. Lets hope something good comes out of the conference.

[rettikins]

Great post, EBS! Those are my thoughts exactly! I'm not holding my breath on BTD, but I do believe favorable data from the liver or breast clinical trials will be presented which will be great reassurance for investors and potential partners alike.
IMO.

[biopharm]

European Cancer Conference : 2013 :
-----------------------------------------------------------------
.... Bayer announced Sept 17 re: abstract at ECC

... and ECC Chairperson - Cornelis van de Velde also had a couple years as Associate Director at the FDA and earlier some ties to MD Anderson
-----------------------------------------------------------------

Bayer to Present Data on Multiple Oncology Compounds at the European Cancer Congress (ECCO-ESMO-ESTRO) 2013

WHIPPANY, N.J., Sept. 17, 2013 /PRNewswire/ -- Bayer HealthCare announced today that data from the company's oncology portfolio, including Nexavar® (sorafenib) tablets, Stivarga® (regorafenib) tablets and Xofigo® (radium Ra 223 dichloride) injection will be presented at the 2013 European Cancer Congress (ECCO/ESMO/ESTRO), September 28 – October 1, in Amsterdam, Netherlands.

http://www.cbs19.tv/story/23451838/bayer-to-present-data-on-multiple-oncology-compounds-at-the-european-cancer-congress-ecco-esmo-estro-2013
------------------------------------------------------------------------------------------------------------------------------------

What's Hot at the European Cancer Congress 2013

Sept 17, 2013

Multidisciplinary collaboration and the future of cancer care in Europe will take a prominent role at the upcoming European Cancer Congress 2013 (ECCO-ESMO-ESTRO), which promises to be a record-breaking meeting.

More than 18,000 delegates are expected to attend and 3303 abstracts were submitted for consideration; there will be an increase in posters and presentations of 37% over previous years.

Attendees can expect to hear presentations that will be practice changing, according to Congress chair Cornelis van de Velde, MD, PhD, president of the European Cancer Organization (ECCO).

Research that is really new, changes practice for prognostic predictive factors, and shows support for new therapies will be presented during the Presidential session," Dr. van de Velde told Medscape Medical News.

The Congress is a primarily a collaboration of 3 major groups — the ECCO, the European Society of Medical Oncology (ESMO), and the European Society for Radiotherapy and Oncology (ESTRO) — and will be held in Amsterdam from September 27 to October 1.

...............
.......
...

http://www.medscape.com/viewarticle/811129

------------------------------------------------------------------------------------------------------------------------------------

Cornelis Jan Hadde van de Velde

Cornelis Jan Hadde van de Velde was born in 1951 and carried out his medical studies in 1975 at the University of Leiden (The Netherlands), completing his Ph.D. Thesis on Model Studies on Breast Cancer Treatment in 1977 Cum Laude. In 1980 he was a Fellow at the M.D.Anderson Hospital in Houston, Depart­ment of Surgery (USA) and registered as a general surgeon in 1982.

He was Visiting Professor at the Seoul National University Hospital, Korea and National Cancer Center Hospital, Tokyo, Japan in 1985 and returned to the University of Leiden two years later as Associate Professor of Surgery, Deputy Tutor. He was appointed as Full Clinical Professor of Surgery and Chairman of the Department of Surgical Oncology, the Leiden University Medical Center in 1988 and became Deputy Chairman, the Division of Surgery in 1991 and Tutor, the Association of Surgeons of the Netherlands in 1988.

From 2008 to 2010, he was President of the European Society of Surgical Oncology (ESSO), and in 2010 was elected President-Elect of ECCO – the European CanCer Organisation.

http://www.ecco-org.eu/Publics-affairs/ECCOs-Policy-Committee/Cornelis-van-de-Velde.aspx
------------------------------------------------------------------------------------------------------------------------------------